Thompson BJ, et al. (2015) DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med 212, 953-70 26008897

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T283-p - CCND3 (mouse) ▲

Modsite: QGPSQTStPTDVTAI SwissProt Entrez-Gene Orthologous residues CCND3 (human): T283‑p, CCND3 iso2 (human): T202‑p, CCND3 iso3 (human): T211‑p, CCND3 iso4 (human): T87‑p, CCND3 (mouse): T283‑p, CCND3 (rat): T284‑p Characterization Methods used to characterize site in vivo:  flow cytometry, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  B lymphocyte, thymocyte Cellular systems studied:  primary cells Species studied:  mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE DYRK1A (human) Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  cell cycle regulation, cell differentiation, induced, transcription, inhibited